Protega Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Protega Pharmaceuticals is a private, pre-revenue biotech founded in 2014, targeting the opioid abuse crisis with its proprietary SentryBond abuse-deterrent formulation technology. Led by industry veterans, the company is developing a line of immediate-release abuse-deterrent opioid products, positioning itself in the high-need but competitive generic and specialty pain management sector. Its success hinges on navigating complex regulatory pathways, achieving product differentiation, and securing commercialization partnerships to bring its therapies to market.

Pain ManagementOpioid Use Disorder

Technology Platform

SentryBond: A proprietary abuse-deterrent oral formulation technology designed to resist physical manipulation (crushing/grinding), chemical extraction, and manipulation for injection.

Opportunities

The ongoing opioid epidemic creates a significant public health need and regulatory push for safer pain management options, particularly in the generic immediate-release opioid market.

Successfully developing a differentiated abuse-deterrent formulation could allow Protega to capture market share and potentially command a pricing premium from payers focused on reducing misuse-related costs.

Risk Factors

Key risks include the high regulatory bar for proving abuse-deterrent claims to the FDA, intense competition from larger, well-established pharmaceutical companies with similar technologies, and the financial uncertainty inherent in a private, pre-revenue company dependent on raising capital to fund development.

Competitive Landscape

Protega operates in the competitive abuse-deterrent formulation (ADF) market, competing against both large branded pharmaceutical companies (e.g., Collegium, Purdue) and generic manufacturers developing their own ADF technologies. Differentiation and proving superior or cost-effective deterrence will be critical to gaining traction.

More companies in Small Molecule Drugs →More companies in United States →